The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial
LJ Sjamsoedin, L Heijnen, EP Mauser-Bunschoten, JL van Geijlswijk, H van Houwelingen, P van Asten, and JJ Sixma
We designed a double-blind trial to study the effect of an "activated" prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in hemophiliacs with antibodies to factor VIII. Fifteen patients received either FEIBA or the control preparation (a nonactivated prothrombin-complex concentrate) for a total of 150 bleeding episodes (four mucocutaneous bleeding, 117 joint bleeding, and 29 muscle bleeding). In 64 per cent of the episodes, FEIBA was judged by the physician to be effective; the control preparation was perceived as effective in 52 per cent of the episodes in which it was used. Pairwise comparison of FEIBA and the control preparation for bleeding in the same joint or muscle showed a significantly better result with FEIBA (P = 0.0085). Joint mobility after the use of FEIBA was significantly improved (P = 0.006). There was a high incidence of hepatitis (three of the 15 patients) and of transient disturbances of liver function (nine of 15) during the 15-month observation period.
This article has been cited by other articles:
Hoots, W. K.
(2007). A "joint" statement on inhibitor-bypassing therapy. Blood
109: 395-396
[Full Text]
Astermark, J., Donfield, S. M., DiMichele, D. M., Gringeri, A., Gilbert, S. A., Waters, J., Berntorp, E., for the FENOC Study Group,
(2007). A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood
109: 546-551
[Abstract][Full Text]
Yee, A. J, Kuter, D. J
(2006). Successful Recovery After an Overdose of Argatroban. The Annals of Pharmacotherapy
40: 336-339
[Abstract][Full Text]
Roberts, H. R., Monroe, D. M., White, G. C.
(2004). The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood
104: 3858-3864
[Abstract][Full Text]
Gringeri, A., Mantovani, L. G., Scalone, L., Mannucci, P. M.
(2003). Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood
102: 2358-2363
[Abstract][Full Text]
Einhorn, L. H.
(2002). Inaugural Article: Curing metastatic testicular cancer. Proc. Natl. Acad. Sci. USA
99: 4592-4595
[Abstract][Full Text]
Mannucci, P. M.
(2002). Ham-Wasserman Lecture : Hemophilia and Related Bleeding Disorders: A Story of Dismay and Success. ASH Education Book
2002: 1-9
[Abstract][Full Text]
Mannucci, P. M., Tuddenham, E. G.D.
(2001). The Hemophilias -- From Royal Genes to Gene Therapy. NEJM
344: 1773-1779
[Full Text]
Aledort, L. M., Green, D., Teitel, J. M.
(2001). Unexpected Bleeding Disorders. ASH Education Book
2001: 306-321
[Abstract][Full Text]
Colowick, A. B., Bohn, R. L., Avorn, J., Ewenstein, B. M.
(2000). Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood
96: 1698-1702
[Abstract][Full Text]
Hedner, U., Ginsburg, D., Lusher, J. M., High, K. A.
(2000). Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia. ASH Education Book
2000: 241-265
[Abstract][Full Text]
Hoyer, L. W.
(1994). Hemophilia A. NEJM
330: 38-47
[Full Text]
Einhorn, L. H.
(2002). Inaugural Article: Curing metastatic testicular cancer. Proc. Natl. Acad. Sci. USA
99: 4592-4595
[Abstract][Full Text]
